Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Find studies

Showing 51–75 of 384 studies in Prevention and risk · tagged Prevention (page 3 of 16) · 29,780 in the whole library · How the 0–100 score works

Download bibliography of these 384 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

What “Prevention and risk” covers

Prevention and risk — What might lower the risk of dementia — and what happened when those things were properly tested.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Interventions for preventing delirium in hospitalised patients

✓ Peer-reviewed alzhub usefulness score 69 out of 100. The Cochrane database of systematic reviews 2007-04-18

It is associated with increases in mortality, physical morbidity, length of hospital stay, institutionalisation and costs to healthcare providers. 4 key findings →

Participants: 833 Evidence: high

Is physical activity a potential preventive factor for vascular dementia? A systematic review

✓ Peer-reviewed alzhub usefulness score 69 out of 100. Aging & mental health 2010-05-01

We conclude that there is evidence supporting the hypothesis that physical activity is likely to prevent the development of VaD, and should be highlighted as part of secondary prevention programmes in people at risk for cerebrovascular disease. 4 key findings →

Design: meta-analysis Participants: 1,378 Evidence: high

This retrospective cohort study is to investigate the association between herpes simplex virus (HSV) infections and dementia, and the effects of anti-herpetic medications on the risk involved, using Taiwan's National Health Insurance Research Database (NHIRD). 4 key findings →

Design: cohort study Participants: 33,448 Evidence: moderate

In the seven longitudinal studies assessing the effect of antihypertensive medication on cognitive impairment or cognitive decline, antihypertensive drugs appeared to be beneficial. 4 key findings →

Design: systematic review Participants: 1,346,176 Evidence: high

Asundexian for Secondary Stroke Prevention

✓ Peer-reviewed alzhub usefulness score 68 out of 100. New England Journal of Medicine 2026-04-15

Among 12,327 patients who underwent randomization (6162 to the asundexian group and 6165 to the placebo group), the incidence of ischemic stroke was lower in the asundexian group than in the placebo group (6.2% vs. 8.4%; cause-specific hazard ratio, 0.74; 95% confidence interval [CI], 0.65 to 0.84; P<0.001). 5 key findings →

Design: clinical trial Participants: 12,327 Evidence: low

Hearing Loss and Falls

✓ Peer-reviewed alzhub usefulness score 68 out of 100. JAMA Otolaryngology–Head & Neck Surgery 2025-03-20

A total of 5 071 935 participants were included from 27 studies; approximately 49.2% of participants were female, and 14 studies were conducted in Asia, 7 in North America, 3 in Europe, and 3 in Oceania, represented by Australia. 5 key findings →

Design: systematic review Participants: 935 Evidence: high

As there is currently no cure for dementia, there is an urgent need for preventive strategies. 5 key findings →

Design: case-control study Evidence: moderate

A combination of modifiable vascular risk factors in midlife is highly predictive of the likelihood of dementia decades later. 1 key finding →

Design: cohort study Participants: 2,767 Evidence: moderate

Vascular factors predict rate of progression in Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 67 out of 100. Neurology 2007-11-01

Atrial fibrillation, hypertension, and angina were associated with a greater rate of decline and may represent modifiable risk factors for secondary prevention in Alzheimer disease. 3 key findings →

Design: longitudinal study Participants: 135 Evidence: moderate

Evidence that short-term, single-component physical activity interventions promote cognitive function and prevent cognitive decline or dementia in older adults is largely insufficient. 2 key findings →

Evidence: low

The 2024 UK clinical guideline for the prevention and treatment of osteoporosis

✓ Peer-reviewed alzhub usefulness score 67 out of 100. Archives of Osteoporosis 2025-09-08

Review of the evidence and recommendations are provided for the diagnosis of osteoporosis, fracture-risk assessment and intervention thresholds, management of vertebral fractures, non-pharmacological and pharmacological treatments, including duration and monitoring of anti-resorptive therapy, glucocorticoid-induced osteoporosis, as well as models of care for fracture prevention. 5 key findings →

Design: meta-analysis Evidence: high

Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission

✓ Peer-reviewed alzhub usefulness score 66 out of 100. The Lancet 2024-08-10

This expert commission synthesized decades of population-level (observational) research to estimate how much dementia risk could theoretically be reduced by addressing 14 modifiable risk factors across life, from childhood education to late-life social isolation. 3 key findings →

Design: systematic-review Evidence: moderate

In this cohort study, high adherence to a flavonoid-rich diet score was associated with a lower risk of dementia, with reductions more pronounced in individuals with a high genetic risk, hypertension, and depressive symptoms. 5 key findings →

Design: cohort Participants: 121,986 Evidence: moderate

Educational Attainment and Dementia: Mediation by Mid-Life Vascular Risk Factors

✓ Peer-reviewed alzhub usefulness score 66 out of 100. Annals of Neurology 2023-04-27

A substantial proportion of the relationship between education and dementia was mediated through mid-life vascular risk factors. 2 key findings →

Design: cohort Participants: 13,368 Evidence: moderate

In the cohort analyses, 891 incident dementia cases were identified over 166,762 person-years. 4 key findings →

Design: meta-analysis Participants: 207,981 Evidence: moderate

Cognitive exercise training in healthy older individuals produces strong and persistent protective effects on longitudinal neuropsychological performance. 3 key findings →

Design: longitudinal study Participants: 54 Evidence: high

Greater understanding of the risk factors and mechanisms of incident dementia in stroke survivors is needed for prevention and management. 3 key findings →

Design: longitudinal study Participants: 355 Evidence: moderate

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 29,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 29,780 records, built mostly from automated pulls of Europe PMC (63.8% of the library) and OpenAlex (17.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,037 records (3.5% of the library) are not peer-reviewed — 964 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed